Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)The purpose of this study is to test the safety and efficacy of a new drug (CSL112, also known as Apolipoprotein A-I) in participants with acute coronary syndrome. Recruiting Principal Investigator Christopher FordyceBody Locations and Systems Angina, Heart AttackArea VancouverAge 18 and above